Details werden geladen...
Candel reports prostate cancer drug's long-term data ahead of FDA filing
Candel Therapeutics' CEO says long-term data bode well for its prostate cancer drug aglatimagene ahead of an FDA submission.
Ähnliche Seiten
Detection of missed deaths in cancer registry data to reduce bias in long-term survival estimation
https://edoc.rki.de/handle/176904/13138
FDA approves Pfizer and Arvinas' breast cancer drug despite underwhelming data
https://endpoints.news/fda-approves-pfizer-and-arvinas-breast-cancer-drug-despite-underwhelming-data/
UniQure Says FDA Rejects Phase I/II Data As Sufficient For AMT-130 Filing | 02.03.26 | finanzen.ch
https://www.finanzen.ch/nachrichten/aktien/uniqure-says-fda-rejects-phase-i-ii-data-as-sufficient-for-amt-130-filing-1035887419
FDA officials push for long-term monitoring of autoimmune patients receiving CAR-T therapy
https://www.statnews.com/2026/02/02/fda-long-term-follow-up-studies-car-t-therapy-automimmune-disorders/
Candel Therapeutics Reports Extended Clinical Benefit Over Multiple Clinical Endpoints in Patients from Phase 3 Trial of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer Under Prolong...
https://www.manilatimes.net/2026/05/16/tmt-newswire/globenewswire/candel-therapeutics-reports-extended-clinical-benefit-over-multiple-clinical-endpoints-in-patients-from-phase-3-trial-of-aglatimagene-besadenovec-can-2409-in-localized-prostate-cancer-under-prolonged-follow-up-at-aua-2026-annual-meeting/2345287